XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Related Party Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2022
Mar. 24, 2022
Jun. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jul. 31, 2022
Feb. 28, 2022
Dec. 31, 2021
Mar. 31, 2017
Amortization of Debt Discount (Premium)           $ 1,897,000 $ 2,723,000        
Interest Paid, Excluding Capitalized Interest, Operating Activities           180,000 180,000        
ImmuneCyte [Member]                      
Percent of Ownership Interest Transferred   8.64%                  
Royalty, Percent of Annual Net Sales, US Patents   7.50%                  
Royalty, Percent of Annual Net Sales, Other Licensed Intellectual Property   5.00%                  
Convertible Note Converted into Common Stock [Member]                      
Debt Conversion, Original Debt, Amount     $ 3,000,000                
Debt Conversion, Converted Instrument, Shares Issued     10,552,234                
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]                      
Line of Credit Facility, Maximum Borrowing Capacity                     $ 10,000,000
Long-Term Line of Credit, Total       $ 7,000,000   $ 7,000,000       $ 10,000,000  
Debt Instrument, Interest Rate, Stated Percentage       22.00%   22.00%          
Debt Instrument, Convertible, Conversion Price $ 0.28   $ 0.28         $ 0.21 $ 0.64   $ 1.80
Debt Instrument, Unamortized Discount, Total $ 2,475,000   $ 2,475,000         $ 1,075,000 $ 213,000    
Amortization of Debt Discount (Premium) $ 742,000     $ 940,000   $ 1,897,000          
Interest Paid, Excluding Capitalized Interest, Operating Activities       394,000 $ 562,000 1,496,000 $ 1,668,000        
Interest Payable       $ 1,099,000   $ 1,099,000       $ 2,231,000